HDI Publications by date

Search will default to “all years” unless you filter by a specific year below.

Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer

Hend Hassan; Tameera Rahman; Andrew Bacon; Craig Knott; Isaac Allen; Catherine Huntley; Lucy Loong; Yvonne ...

Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe

Girard N, Wolf J, Kim TM, Leighl N, Knott CS, Li T, Cabrieto J, Diels J, Sermon J, Mahadevia P, Schioppa CA, ...

Trends in incidence, treatment and survival of Merkel cell carcinoma epidemiology in England 2004-2018

Mistry K, Levell NJ, Hollestein, Wakkee M, Hijsten T, Knott CS, et al. Trends in incidence, treatment and survival ...

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Chouaid, C., Bosquet, L., Girard, N. et al. An Adjusted Treatment Comparison Comparing Amivantamab Versus ...

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996–2020

Lucy Loong, Catherine Huntley, Fiona McRonald, Francesco Santaniello, Joanna Pethick, Bethany Torr, Sophie ...

Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasia.

Clements K, Dodwell D, Hilton B, Stevens-Harris I, Pinder S, Wallis MG, et al.BMJ Open 2022;12: ...

Second primary cancer risks for female and male breast cancer survivors

Isaac Allen; Tameera Rahman; Andrew Bacon; Craig Knott; Sophie Jose; Sally Vernon; Hend Hassan; Catherine ...

Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations

Girard N, Wolf J, Kron A, Scheffler M, Knott CS Bosquet L et al. Amivantimab versus real-world clinical practice ...

Characteristics, treatment patterns and outcomes of patients with newly diagnosed advanced ovarian cancer (aOC) in England

Angela Whittle, Betina Blak, Amy Zalin-Miller, Orlaith Condon (2022) ‘Characteristics, treatment patterns and ...

The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)—results from the UK Sloane Project.

Shaaban AM, Hilton B, Clements K, Dodwell D, Sharma N, Kirwan C, et al.Br J Cancer 127, 2125–2132, 2022. ...